110 related articles for article (PubMed ID: 34320709)
1. The Need for Effective Adjuvant Therapy in Uterine Leiomyosarcoma: A Single-centre Experience.
Eraslan E; Yildiz F; Ilhan A; Dogan M
J Coll Physicians Surg Pak; 2021 Aug; 31(8):926-931. PubMed ID: 34320709
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Chantharasamee J; Wong K; Potivongsajarn P; Qorbani A; Motamed N; Brackert S; Cohen J; Chmielowski B; Kalbasi A; Rao J; Nelson S; Singh A
Cancer Med; 2022 Aug; 11(15):2906-2912. PubMed ID: 35307963
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
4. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
5. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
6. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
Cybulska P; Sioulas V; Orfanelli T; Zivanovic O; Mueller JJ; Broach VA; Long Roche KC; Sonoda Y; Hensley ML; O'Cearbhaill RE; Chi DS; Alektiar KM; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2019 Aug; 154(2):333-337. PubMed ID: 31200927
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
8. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
[TBL] [Abstract][Full Text] [Related]
9. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
10. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma.
Sisic L; Blank S; Nienhüser H; Haag GM; Jäger D; Bruckner T; Ott K; Schmidt T; Ulrich A
Surg Oncol; 2020 Jun; 33():177-188. PubMed ID: 28684226
[TBL] [Abstract][Full Text] [Related]
11. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
12. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Ingham M; Allred JB; Chen L; Das B; Kochupurakkal B; Gano K; George S; Attia S; Burgess MA; Seetharam M; Boikos SA; Bui N; Chen JL; Close JL; Cote GM; Thaker PH; Ivy SP; Bose S; D'Andrea A; Marino-Enriquez A; Shapiro GI; Schwartz GK
J Clin Oncol; 2023 Sep; 41(25):4154-4163. PubMed ID: 37467452
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the benefit of adjuvant chemotherapy in patients with ypT0-1 rectal cancer treated with preoperative chemoradiotherapy.
Jeon YW; Park IJ; Kim JE; Park JH; Lim SB; Kim CW; Yoon YS; Lee JL; Yu CS; Kim JC
World J Gastrointest Surg; 2021 Sep; 13(9):1000-1011. PubMed ID: 34621476
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
[TBL] [Abstract][Full Text] [Related]
16. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas.
Hensley ML
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):773-82. PubMed ID: 21752717
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
19. Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma.
Gracia M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Cusine-Lopez L; Novak Z; Dallaku K; Zapardiel I;
Int J Gynaecol Obstet; 2023 Dec; 163(3):868-874. PubMed ID: 37485666
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant management of operated uterine sarcomas: A single institution experience.
Cordoba A; Prades J; Basson L; Robin YM; Taïeb S; Narducci F; Hudry D; Bresson L; Chevalier A; Le Tinier F; Mirabel X; Lartigau É; Penel N; Leblanc É
Cancer Radiother; 2019 Sep; 23(5):401-407. PubMed ID: 31351809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
